**Abstract:** The gut microbiota is increasingly recognized as an important modulator of human health. As such, there is a growing need to identify effective means of selectively modifying gut microbial communities. Bacteriophages, which were briefly utilized as clinical antimicrobials in the early 20th century, present an opportunity to selectively reduce populations of undesirable microorganisms. However, whether intentional consumption of specific bacteriophages affects overall gut ecology is not yet known. Using a commercial cocktail of *Escherichia coli*-targeting bacteriophages, we examined their effects on gut microbiota and markers of intestinal and systemic inflammation in a healthy human population. In a double-blinded, placebo-controlled crossover trial, normal to overweight adults consumed bacteriophages for 28 days. Stool and blood samples were collected and used to examine inflammatory markers, lipid metabolism, and gut microbiota. Reductions in fecal *E. coli* loads were observed with phage consumption. However, there were no significant changes to alpha and beta diversity parameters, suggesting that consumed phages did not globally disrupt the microbiota. However, specific populations were altered in response to treatment, including increases in members of the butyrate-producing genera *Eubacterium* and a decreased proportion of taxa most closely related to *Clostridium perfringens*. Short-chain fatty acid production, inflammatory markers, and lipid metabolism were largely unaltered, but there was a small but significant decrease in circulating interleukin-4 (IL-4). Together, these data demonstrate the potential of bacteriophages to selectively reduce target organisms without global disruption of the gut community.

**Keywords:** bacteriophage; cytokines; gut microbiota; gastrointestinal; inflammation; short-chain fatty acid

1. Introduction

Intestinal health and the gut microbiota have increasingly been linked to various chronic health outcomes. Imbalances in the gut microbiota resulting from poor diet, stress, antibiotic use, and other
lifestyle and environmental factors are associated with the development of intestinal inflammation and bowel irregularities [1,2]. Several autoimmune and metabolic conditions and even mental health may also be rooted in the gut and influenced by its microbial residents [2]. As a result, there is a growing interest in identifying dietary supplements that favorably modulate gut microbial populations. According to Transparency Market Research, the U.S. market for probiotics, prebiotics, and other digestive aids currently exceeds $68.8 billion and is expected to reach $83.5 billion by 2022 [3]. Thus, there exists a critical need to identify safe and effective methods of manipulating gut microbiota to promote overall health and well-being.

Bacteriophages (or phages) are among the candidates being explored as potential microbial modifiers in promoting intestinal health [4]. These ubiquitous, bacteria-targeting viruses exhibit a high degree of host specificity, suggesting utility for selectively reducing pathogenic or pro-inflammatory bacteria in the microbial milieu. The antibacterial activity of phages was first observed in the waters of the Ganges and Jumna rivers in India in 1896 [5]. In 1917, Felix d’Herelle demonstrated their clinical relevance by isolating and applying phages to treat numerous bacterial infections [6]. However, despite promising early results, the concept of phage therapy lost momentum with the introduction of broad spectrum antibiotics, which allowed the treatment of bacterial diseases without the need to identify a specific causal organism [7]. The host specificity of phages, which has limited their widespread application as clinical antimicrobials, may be advantageous when considering their use as microbiota-modulating dietary supplements. While antibiotics can cause or exacerbate microbiota imbalances or dysbiosis [8], phages offer the opportunity to subtly and selectively modify the gut microbiota. Several bacteriophages are “Generally Recognized As Safe” (GRAS) for human consumption by the U.S. Food and Drug Administration (FDA). Recently, we demonstrated that oral ingestion of a bacteriophage cocktail in dietary supplement form was safe and tolerable in a healthy adult population [9].

The objective of the current study was to determine how daily consumption of supplemental *Escherichia coli*-targeting phages (commercially sold as PreforPro®) influences the gut microbiota of healthy adults with self-reported gastrointestinal distress. In addition, we determined the effects on microbial production of short-chain fatty acids (SCFAs), as well as explored whether phage consumption alters lipid metabolism and parameters of local and systemic inflammation. Here, we report that 28 days of phage consumption did not substantially alter the global gut microbiota profiles of most individuals, but did reduce populations of the target bacteria, *E. coli*, as well as modify a number of individual bacterial species, including an increase in amplicon sequence variants (ASVs) mapping to *Eubacterium spp.*, which is one of the most abundant genera in the healthy human gut [10]. We also saw a reduction in the circulating pro-inflammatory cytokine interleukin 4 (II-4), which has been associated with autoimmune and allergic responses in human populations [11]. These data highlight the potential of bacteriophages for selective modification of targeted microbial species without inducing dysbiosis.

2. Materials and Methods

2.1. Participant Characteristics

Forty-three healthy adults aged 18–65 with self-reported gastrointestinal issues were enrolled in the study. Eligibility was determined by a telephone or in-person screening prior to obtaining informed consent. Exclusion criteria included (a) a previous diagnosis of gastrointestinal or metabolic conditions, cancer, liver, or kidney diseases; (b) pregnancy or breastfeeding; (c) smoking; (d) use of antibiotics in the last 2 months; and (e) current medication or dietary supplement use that may impact gut microbiota. Participants were asked to maintain their regular diet and exercise habits throughout the study, refrain from supplemental prebiotics or probiotics, and limit alcohol consumption to 1 drink per day or no more than 7 drinks per week. Additional study criteria and participant demographics are reported in Gindin et al. [9]. Of the total enrolled participants (n = 43), 36 completed at least one
2.2. Study Design

The study was conducted as a randomized, double-blind, placebo-controlled crossover intervention trial, with two 28 day intervention periods and a washout period of at least two weeks between treatments. The treatments consisted of 4 supplemental bacteriophage strains (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae) at a titer of $10^6$ phages per dose included in PreforPro® commercial capsules prepared by Deerland Enzymes (Kennesaw, GA, USA). The placebo was rice maltodextrin and coconut triglycerides, which were also the carrier materials used in the treatment capsules. Participants were asked to consume one 15 mg capsule per day during the treatment and placebo periods. The study was conducted at the Human Performance Clinical Research Laboratory (HPCRL) at Colorado State University. At each clinic visit ($t = 0$ and $t = 28$ days for each intervention period, 4 visits in total), participants provided a fresh stool sample that had been collected at home and returned to the clinic within 24 h of their visit. A fasted blood sample was also collected. Collected stool and plasma samples were stored at $-80$ °C prior to analysis. A detailed study protocol has been previously published [9]. The study protocol was approved by the Institutional Review Board (IRB) for Human Subjects Research at Colorado State University, CSU protocol #16-6666HH, and all participants provided written informed consent prior to beginning the study. The study is also registered at clinicaltrials.gov as NCT03269617 [9].

2.3. DNA Extraction and Sequencing

Collected stool samples were thawed and subsampled with sterile cotton swabs. Fecal DNA was then extracted from the swabs using the FastDNA® KIT (MP Biomedical; Santa Ana, CA, USA) following modified manufacturer’s instructions that included optimization with additional wash steps. Sequencing libraries were constructed by PCR amplification of the V4 region of the 16s rRNA gene using primers 515F and 806R following the protocol for the Earth Microbiome Project [12]. Amplicons were purified using AxyPrep Mag PCR clean-up beads (Axygen; Corning, NY, USA), and amplicons were quantified with a Quanti-iT PicoGreen dsDNA Assay Kit (Invitrogen; Eugene, OR, USA) and pooled in equimolar ratios prior to sequencing at the Colorado State University Genomics Core facility using a 2 × 250 MiSeq flow cell (Illumina, San Diego, CA, USA).

2.4. Microbiota Analysis

Paired-end sequence reads were concatenated, and all combined 16s sequences were filtered, trimmed, and processed with the DADA2 [13] implementation included in the open source bioinformatics tool myPhyloDB version 1.2.1 [14]. Briefly, all primers were removed from each sequence using the open source Python program Cutadapt [15], and amplicon sequence variants (ASVs) were inferred using the default pipeline in DADA2. Each sequence variant identified in DADA2 was classified to the closest reference sequence contained in the GreenGenes reference database (Vers. 13.5_99) using the usearch_global option (minimum identity of 97%) contained in the open source program VSEARCH [16]. Analysis of covariance (ANCOVA), DiffAbund, and principle coordinates analysis (PCoA) analyses were conducted in myPhyloDB, and MicrobiomeAnalyst [17] was used to calculate alpha diversity scores. Data were filtered to remove unassigned reads and phylotypes with ≥25% zeros. The raw sequencing data are available upon request, and links to the metadata and .biom files are included with the Supplementary Materials.

2.5. Short-Chain Fatty Acids

Short chain fatty acids (SCFA) were extracted from frozen fecal samples and analyzed as previously described [18]. Briefly, fecal aliquots were extracted in acidified water (pH 2.5) containing an internal standard of 5mM of ethylbutyric acid. Suspended samples were homogenized and
sonicated, followed by centrifugation to remove particulate matter. Supernatant was analyzed on a Gas Chromatograph with Flame Ionization Detection (GC-FID; Agilent 6890 Plus GC Series, Agilent 7683 Injector series, GC Column: TG-WAXMS A 30mx 0.25mm × 0.25µm). The run program was as follows: Initial temp = 100 °C for 1 min, max temp = 300 °C, equilibration time = 1 min with a ramp rate of 8.0 for 1 min to a final temp of 180 °C, followed by a ramp rate of 20.0 to a final temp of 200 °C for 5 min. Post temperature was 50 °C. The front inlet was split (10:1), 240 °C, 16.57psi. Peak areas were normalized to the internal standard (5 mM ethyl butyric acid, Retention Time (RT) = 9.2) and quantified using standard curves (acetic acid, RT = 5.5; propionate, RT = 6.7; butyrate, RT = 7.7) from dilutions of commercial stocks.

2.6. Fecal Triglycerides

Fecal triglycerides were assessed using the Triglycerides Assay Kit (Cayman Chemicals, Ann Arbor, MI). Briefly, 75 mg of homogenized fecal sample was suspended in 1xNP40 reagent containing protease inhibitors. Samples were centrifuged at 4 °C for 10 min at 10,000 rpm. Supernatant was diluted 1:5 with 1xNP40, and absorbance at 530–550nm was measured after incubation for 15 min at room temperature. Triglyceride quantity was determined by fitting to standard curves.

2.7. Local Inflammation and Immune Responses

Fecal secretory immunoglobulin A (sIgA) and fecal calprotectin were analyzed using the Human Secretory IgA ELISA Assay Kit and Calprotectin ELISA Assay kits (Eagle Biosciences, Amherst, NH, USA).

2.8. Systemic Inflammation

Systemic inflammation was assessed by measuring plasma levels of C-reactive protein (CRP), as well as several chemokines and cytokines. CRP levels were assessed using Human hsCRP ELISA kits (BioVender LLC., Asheville, NC, USA) according to the manufacturer’s instructions. In addition, 13 different chemokines and cytokines, which included GM-CSF, IFNγ, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, and TNF-α, were measured using the Milliplex MAP Human High Sensitivity T Cell panel (Millipore Sigma, Burlington, MA, USA). All samples were processed according to the manufacturers’ protocols and analyzed on a Luminex instrument (LX200; Millipore, Austin, TX, USA).

2.9. Plasma Lipids

Lipid panels (total cholesterol (TC), high-density lipoprotein cholesterol (HDL), triglycerides (TRIGs), nonhigh-density lipoprotein cholesterol (nHDL), total cholesterol/HDL ratio (TC/HDL), low-density lipoprotein cholesterol (LDL), and very low-density lipoprotein cholesterol (VLDL)) were assayed within one hour of blood collection using a Piccolo Xpress Chemistry Blood Analyzer (Abaxis, Union City, CA, USA).

2.10. Statistical Analysis

To evaluate the effects of the starting sequence, differences between baseline levels were assessed for each sequence (A-B, B-A). Continuous data were tested for normality prior to performing linear regression analysis. A linear mixed model approach, controlling for sequence and repeated measures, was used to compare treatment effects within each time point and between time points within a treatment group. A p-value of 0.05 was used to assess statistical significance. Prior to statistical analysis, microbiota data were normalized using Laplace smoothing followed [19] by subsampling with replacement (rarefaction (keep) command) in MyPhyloDB [14]. Data were rarefied to 31,037 sequence reads using 100 iterations. Amplicon sequence variants (ASVs) that were present in less than 25% of the total samples were excluded from analyses. An analysis of covariance (ANCOVA)
model was used to assess taxonomic differences across treatment groups, and a genewise negative binomial generalized linear model (GLM) (EdgeR [20]) was used to determine differential distribution of taxa between treatments. Measures of alpha (CHAO1 estimates, Shannon and Simpson diversity indices) and beta diversity (Bray–Curtis distances) were statistically analyzed using nonparametric Kruskal–Wallis tests.

3. Results

Study compliance and the safety and tolerability of phage consumption have previously been reported [9]. Here, we present the results of the 16s rRNA sequencing and targeted metabolite analysis from stool samples as well as plasma lipids and markers of inflammation.

3.1. Gut Microbiota and Metabolite Analysis

Bacterial sequences were classified to seven phyla, with the majority being represented by Firmicutes, followed by Bacteroidetes and minor components including Actinobacteria, Proteobacteria, and Verrucomicrobia. There were no significant differences in bacterial taxa between treatment groups and time points (Figure 1A and Figure S1). In addition, richness estimates (CHAO1) and α-diversity, calculated as Shannon and Simpson’s indices, did not vary across groups (Table S1). PCoA visualization of Bray–Curtis distances did not show any significant clustering between treatment groups or time points (Figure 1B).

![Figure 1.](image)

Figure 1. (A) Relative abundance of bacterial phyla detected in stool samples at baseline and after 28 days for both phage (treatment) and placebo study periods. No significant differences were detected by analysis of covariance (ANCOVA) at \( p < 0.05 \). (B) Principle coordinates analysis (PCoA) with nonmetric dimensional scaling of species-level Bray–Curtis distances. Stress = 0.191; perMANOVA (1000 permutations) \( Pr (>F) = 0.996 \).

Because the supplemented phage cocktail specifically targeted \( E. coli \), we identified ASVs in each sample that mapped to \( E. coli \) (gg_111717). Only 21 total participants had detectable levels of \( E. coli \) prior to starting the treatment period. Baseline levels varied significantly among participants, ranging from 0.01%–3.2% of total reads. The response rate was ~71%, with 15 of the 21 participants that had detectable levels of \( E. coli \) prior to starting the treatment period showing reduced or undetectable levels after treatment (responder subpopulation), while only 47% of the individuals with detectable levels of \( E. coli \) prior to the placebo period showed reduction after 28 days. Overall, \( E. coli \) levels were significantly reduced after phage treatment (\( p = 0.03 \) for the total study population and \( p = 0.02 \) when only including participants with baseline \( E. coli \), but not after placebo (\( p = 0.85 \) for the total study population and \( p = 0.78 \) for participants with baseline \( E. coli \)) (Figure 2). On average, the number of
*E. coli* reads were reduced by ~40% after treatment and by only 14% after the placebo, although there was a great deal of variability between participants.

![Figure 2](image-url)

**Figure 2.** (A) Percent of total reads represented by amplicon sequence variants (ASVs) mapping to *Escherichia coli* for each treatment and time point. (B) Change in *E. coli* levels from baseline values after treatment or placebo consumption. Data represents only individuals with baseline *E. coli* levels (*n* = 21). Error bars represent SEM.

Several microbial taxa were significantly correlated with fecal levels of *E. coli*, regardless of intervention period. *Oxalobacter formigenes* and ASVs assigned to the Lachnospiraceae family were negatively correlated with *E. coli* populations. Conversely, several ASVs identified as belonging to the Ruminococcaceae family were positively correlated with *E. coli*, as was *Desulfovibrio* (Figure 3).

![Figure 3](image-url)

**Figure 3.** Using Spearman’s rank, several ASVs were found to be significantly negatively correlated (red bars) or positively correlated (blue bars) with *E. coli* ASVs. Significant values were considered *q* < 0.10.

There was only one bacterial ASV that increased significantly (*q* < 0.10) after phage consumption in the responder subpopulation (those who had baseline *E. coli* and saw reductions with treatment), *Bifidobacterium bifidum*, which was ~5.5-fold higher compared to baseline measures (mean *t* = 0.13; mean *t* = 28 = 1.1; log fold change (logFC) = 2.7, Counts Per Million (CPM) = 8.1, likelihood ratio = 6.7;
False Discover Rate (FDR) = 0.06). There were also several treatment-associated taxa changes noted in the total study population, which included 36 participants that completed at least one arm of the study, regardless of whether E. coli was detected in baseline samples. Most notably, three ASVs representing potentially pathogenic or inflammation-associated taxa were reduced relative to the placebo, including an ASV mapping to *Clostridium perfringens*, a food-borne pathogen and minor component of the commensal flora [21], which was reduced by about 75%. In addition, two ASVs representing species of *Eubacterium* were increased by 4–5-fold after phage consumption compared to the placebo (Figure 4).

To assess functional changes in the microbiota, we also assayed fecal short-chain fatty acid (SCFA) concentrations. Acetate was the most abundant SCFA, averaging 10–20 mM/gram of stool across all treatments and timepoints (Figure S2A). Propionate and butyrate were detected in levels of approximately 2–4 mM/gram of stool (Figure S2B,C). There were no significant differences in any of the SCFAs detected across timepoints or between treatment periods, although there was a trend toward decreased acetate from the baseline level within the placebo period (p = 0.06; *Confidence Interval (CI)* = −0.09 to 3.15).

### 3.2. Stool and Plasma Lipid Profiles

Since the microbiota also plays a role in lipid absorption [22,23], we measured total triglyceride levels in stool. Although there was significant interindividual variability, there were no significant differences in fecal triglycerides across timepoints or between treatment periods (Table 1), although there was a significant period effect noted for participants starting on the placebo and transitioning to the treatment group (p = 0.03; CI = −8.93 to −0.49). Likewise, there were no significant changes across time periods or between treatments for plasma lipids associated with phage consumption. However, there was a statistically significant change in total cholesterol to HDL ratio (TC/H) between the baseline (t = day 0) and day 28 of the placebo period (p = 0.045; CI = 0.00 to 0.18), possibly driven by a trend toward reduced HDL cholesterol during this period (p = 0.08; CI = −3.87 to −1.75) (Table 1). However, these statistical differences are unlikely to have any clinical or biological relevance.

### 3.3. Immunological and Inflammatory Markers

We examined several stool and blood markers indicative of inflammatory state and immunological activity. In stool, we measured calprotectin and secretory immunoglobin A (sIgA). Calprotectin was below the detection limits of our assay for the majority of samples tested (data not shown): sIgA was detectable, and the majority of samples fell within clinically normal ranges (510–2040 µg/mL). Therewere no significant differences in this parameter across timepoints or between treatment periods.
was significantly reduced from baseline after 28 days of phage consumption (hsCRP) as well as a panel of 13 human T-cell-derived cytokines. There were no significant responses across timepoints or between treatments in these parameters, with one exception. Interleukin-4 (Il-4) was significantly reduced from baseline after 28 days of phage consumption (p = 0.002; CI = −15.63 to −3.67) (Table 2).

Table 1. Stool and plasma lipid profiles.

|                      | Treatment (t = 0) | Treatment (t = 28) | Placebo (t = 0) | Placebo (t = 28) |
|----------------------|------------------|-------------------|----------------|-----------------|
| Fecal Triglycerides  | 6.70 (±0.70)     | 8.12 (±0.89)      | 9.25 (±1.14)   | 7.46 (±0.79)    |
| Cholesterol (mg/dL)  | 189.70 (±4.93)   | 187.18 (±4.83)    | 192.03 (±5.76) | 189.35 (±6.08)  |
| LDL (mg/dL)          | 103.48 (±3.56)   | 100.82 (±4.23)    | 106.76 (±4.85) | 103.06 (±4.67)  |
| vLDL (mg/dL)         | 21.20 (±1.82)    | 20.52 (±1.87)     | 19.62 (±1.94)  | 19.85 (±1.94)   |
| HDL (mg/dL)          | 65.06 (±2.51)    | 65.24 (±2.58)     | 65.74 (±2.33)  | 63.91 (±2.84)   |
| nHDLc (mg/dL)        | 123.61 (±4.89)   | 122.85 (±4.98)    | 126.21 (±5.68) | 125.62 (±5.40)  |
| TC/H                 | 3.03 (±0.13)     | 3.01 (±0.14)      | 3.02 (±0.13)   | 3.11 (±0.14)    |
| Plasma Triglycerides | 99.94 (±9.11)    | 102.61 (±9.46)    | 97.74 (±9.70)  | 99.41 (±9.77)   |

Table 2. Plasma C-reactive protein (CRP) and cytokines.

|                      | Treatment (t = 0) | Treatment (t = 28) | Placebo (t = 0) | Placebo (t = 28) |
|----------------------|------------------|-------------------|----------------|-----------------|
| hsCRP (mg/mL)        | 1.76 (±0.51)     | 1.79 (±0.52)      | 1.56 (±0.41)   | 2.45 (±0.68)    |
| GMCSF (pg/mL)        | 80.69 (±9.99)    | 80.54 (±10.35)    | 83.17 (±9.78)  | 80.59 (±10.10)  |
| IFN-γ (pg/mL)        | 12.67 (±1.12)    | 12.29 (±1.02)     | 14.21 (±1.86)  | 13.81 (±1.89)   |
| II-10 (pg/mL)        | 24.13 (±3.30)    | 23.53 (±2.85)     | 26.03 (±3.75)  | 24.83 (±3.84)   |
| II-12 (pg/mL)        | 3.57 (±0.33)     | 3.57 (±0.32)      | 3.75 (±0.35)   | 3.55 (±0.37)    |
| II-13 (pg/mL)        | 23.05 (±5.53)    | 22.16 (±5.71)     | 25.39 (±6.06)  | 24.5 (±5.73)    |
| II-1β (pg/mL)        | 1.76 (±0.13)     | 1.71 (±0.10)      | 1.85 (±0.13)   | 1.73 (±0.12)    |
| II-2 (pg/mL)         | 2.24 (±0.14)     | 2.15 (±0.18)      | 2.46 (±0.28)   | 2.36 (±0.31)    |
| II-4 (pg/mL)         | 69.48 (±5.75)    | 59.83 (±4.43)     | 63.79 (±4.95)  | 61.71 (±3.88)   |
| II-5 (pg/mL)         | 8.16 (±3.26)     | 5.55 (±1.33)      | 7.85 (±2.71)   | 6.38 (±1.57)    |
| II-6 (pg/mL)         | 3.37 (±0.33)     | 3.43 (±0.33)      | 3.76 (±0.38)   | 3.82 (±0.41)    |
| II-7 (pg/mL)         | 13.37 (±1.07)    | 13.39 (±1.14)     | 13.91 (±1.16)  | 13.35 (±1.12)   |
| II-8 (pg/mL)         | 4.14 (±0.70)     | 4.24 (±0.77)      | 4.51 (±0.83)   | 4.45 (±0.81)    |
| TNFα (pg/mL)         | 4.45 (±0.29)     | 4.18 (±0.25)      | 4.23 (±0.24)   | 4.09 (±0.26)    |

Values represent mean (± SEM); Statistically significant differences are denoted by different letters (p < 0.01). II: Interleukin; GMCSF: Granulocyte Macrophage Colony Stimulating Factor; TNF: Tumor Necrosis Factor.

4. Discussion

Bacteriophages offer a novel and selective means of modifying the gut microbiota, thereby influencing the intestinal environment without causing global perturbations that can lead to microbial dysbiosis. In the current study, we confirmed that phage treatment was not associated with global perturbations in the gut microbiota, as evidenced by a lack of differences in community descriptors such as richness and α-diversity between treatments or over time. Furthermore, no clustering of groups was apparent on a PCoA plot of Bray–Curtis distances. On the contrary, disruption of microbial communities by antibiotics and other pharmaceutical treatments can predispose individuals to dysbiosis and create ecological niches where pathogens can establish a foothold, as is commonly
seen with *Clostridium difficile* infections [8,24]. Thus, phages represent a novel means of selectively modifying the microbiota without causing global disruptions to community structure.

Although no global changes to the microbiota were apparent with phage treatment, there were a few significant alterations in certain members of the microbial community. Importantly, *E. coli*, which is the target host for the consumed phage consortium, was significantly reduced at the end of the treatment period. Populations of several bacterial taxa were also positively or negatively correlated with levels of *E. coli*. While it is difficult to discern whether there were specific ecological interactions driving these associations, both *E. coli* and sulfate-reducing bacteria (SRB), such as *Desulfovibrio*, have been associated with higher clinical activity indices and sigmoidoscopy scores in rectal biopsies of patients with Inflammatory Bowel Disease (IBD) [25–27]. One study also reported higher *Clostridium perfringens* and lower *Eubacterium* spp. associated with disease severity [25]. Interestingly, consumption of bacteriophages in the current study resulted in a more than 4-fold reduction of *C. perfringens* as well as 4–5-fold increases in two ASVs mapping to taxa in the genus *Eubacterium*. *Eubacterium* reductions have also been associated with several inflammatory conditions in the gastrointestinal tract [28,29]. *Eubacterium* spp. are butyrate producers, and as such may be important in stimulating enterocyte turnover and maintaining tight barrier junctions. However, we did not observe an overall increase in stool butyrate with the bacteriophage treatment. This could have been due to a high level of interindividual variation in SCFA production masking responses at the population level. It may also have been due to insufficient levels of fiber intake, as this is the substrate for SCFA production. Finally, another interesting observation was the positive correlation between the sulfate-reducing bacteria (SRB) *Desulfovibrio* and *E. coli* ASVs across the population. Although the physiological role of SRB in the gastrointestinal tract is still not well understood, it is commonly accepted that production of hydrogen sulfide could have direct inflammatory, cytotoxic, and genotoxic effects in the gut that could reduce epithelial barrier integrity [30]. These data suggest that further investigation of bacteriophages is warranted to determine the therapeutic value of treating individuals with inflammatory bowel conditions.

Another observation associated with phage consumption was a reduction of circulating IL-4. This cytokine is released during Th2 responses, which are associated with the promotion of IgE and eosinophilic responses to atopy [31]. Although the mechanisms relating IL-4 reduction to phage consumption are unclear, some studies have demonstrated that bacterial lipopolysaccharide (LPS) induces IL-4 production via a MyD88 and TRAM-dependent pathway [32]. Although we do not have direct evidence of reduced circulating LPS, we have previously reported lower aspartate aminotransferase (AST) and alkaline phosphatase (ALP) in whole blood samples collected after treatment compared to the placebo control [9]. In a rodent model, AST and ALP increased after exposure to LPS [33]. Circulating LPS is associated with systemic inflammation and increased cytokine release [34]. Therefore, it is plausible that the phage treatment resulted in lower circulating LPS, which may drive reductions in IL-4. These data suggest that future experiments are justified to further explore mechanistic links between IL-4 and phage consumption as well as to examine the effect of the bacteriophage cocktail in a human population with atopic dermatitis and other allergic atopies.

A major strength of the current study was its crossover design, in which each individual served as his or her own control. This was advantageous given the inter-person variability of the microbiota, as well as individual responses to a stimulus. An additional strength of this study design was the double blinding, thus minimizing participant and researcher bias. Despite these strengths, there were several shortcomings that limited our ability to interpret the data. For example, the phage cocktail prescribed has been shown in animal models to reduce target *E. coli* populations and stimulate the growth of probiotic species [35]. However, the variability in detectable baseline levels of both *E. coli* and these probiotic species in our sample pool made it difficult to replicate these findings in a human population. However, this product is currently marketed as a dietary supplement, and thus it is important to determine how it impacts the global microbiota in a healthy population. While we did see a phage-associated increase in taxa mapping to *Bifidobacterium bifidum* in a subpopulation
of responders, examining the influence of the co-administration of phages with particular probiotic species may be necessary to establish whether they enhance probiotic survival and efficacy in the gastrointestinal tract. Another limitation was the lack of a diet and physical activity assessment, as these parameters may influence microbiota composition. While participants were asked to remain on their typical diet and exercise regime and were excluded from the study if they indicated that they were actively trying to lose weight, tracking these metrics would have been an additional measure to assess compliance. Thus, although some of the observed changes in specific bacterial populations may have been in response to changes in these external factors, the study was designed to minimize these effects.

In conclusion, bacteriophage consumption caused minimal disruption to the gut microbiota, but did elicit minor changes that may be viewed as beneficial overall. Specifically, the reduction of \textit{E. coli}, decreased proportions of potentially pro-inflammatory bacteria, and increases in fermentative taxa that are capable of butyrate production suggest a shift toward a healthier gut environment. As gut dysbiosis continues to be associated with human disease and the medical community is confronted with anti-microbial “superbugs”, bacteriophages offer an additional resource to combat these issues. This study merely broaches the edge of this potential, and along with our previously published data [9], confirms the safety and tolerability of phage consumption in a human population. These data support further studies on the microbiota modulatory potential of bacteriophages for use as a dietary supplement and possibly as a therapeutic agent in clinical populations of intestinal inflammation.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2072-6643/11/3/666/s1, Figure S1: Bar plots of relative abundance at varying taxonomic resolutions. Unclassified samples were removed from the analysis at each taxonomic level. Figure S2: Fecal short chain fatty acid levels across treatments and time. Figure S3: Fecal sIgA levels. Table S1: Microbial alpha diversity parameters.

**Author Contributions:** T.C.W. and T.L.W. conceptualized the study, acquired funding, and obtained regulatory board approvals. M.G. served as the clinical coordinator, which included obtaining consent from and scheduling participants, collecting biofluids and anthropomorphic data at clinic visits, and managing data collection and storage. N.D.M.G. and E.F. assisted with clinical sample collection, lipid panels, and blood processing. H.P.F., J.S.V., T.L.W., and S.L. processed wet lab samples and conducted laboratory assays. Microbiota data were analyzed by D.K.M. and T.L.W. Statistical analysis was conducted by S.R. Data interpretation was conducted by T.L.W., D.K.M., H.P.F., and T.C.W. Drafting the manuscript was the responsibility of H.P.F., T.C.W. and T.L.W., with all authors contributing to editing and approving the final manuscript.

**Funding:** Funding for conducting the study was provided by an unrestricted educational grant from Deerland Enzymes to Think Healthy Group, Inc. T.L.W. and H.P.F. were supported by funding from the Karen Morris-Fine Early Career Faculty Success Fund.

**Acknowledgments:** We would like to thank Laurie Biela and Nate Grimm for assistance with scheduling and supplies at the HPCRL, Jessica Metcalf for the donation of sequencing primers, and Justin Lee and Mark Stenglein at the CSU Genomics Core. Finally, we would also like to acknowledge Amy Cheng and Nicholas Rivera for assistance with fecal sample processing. T.C.W. is an adjunct professor in the Department of Nutrition and Food Studies at George Mason University; however, this study was not conducted at GMU.

**Conflicts of Interest:** Funding was provided by Deerland Enzymes to the Think Healthy Group, Inc., through an unrestricted educational grant. T.C.W. is the Principal and CEO of the Think Healthy Group, Inc., a food science and nutrition consulting firm dedicated to advancing cutting-edge research and public health through engagement with industry, academia, government, media, and nongovernmental organizations. All conflicts can be found on his website at www.drtaylorwallace.com. Deerland Enzymes played no role in the study design, data collection, analysis, or interpretation and presentation of results. All other authors declare no conflicts of interest.

**References**

1. Gentile, C.L.; Weir, T.L. The gut microbiota at the intersection of diet and human health. *Science* **2018**, *362*, 776–780. [CrossRef] [PubMed]
2. Schippa, S.; Conte, M.P. Dysbiotic events in gut microbiota: Impact on human health. *Nutrients* **2014**, *6*, 5786–5805. [CrossRef] [PubMed]
3. Nutraceutical News. Available online: http://www.nutra-insurance.com/nutraceutical-news (accessed on 25 February 2019).
4. Gordillo Altamirano, F.L.; Barr, J.J. Phage Therapy in the Postantibiotic Era. *Clin. Microbiol. Rev.* 2019, 32, e00066-18. [CrossRef] [PubMed]

5. Abedon, S.T.; Thomas-Abedon, C.; Thomas, A.; Mazure, H. Bacteriophage prehistory: Is or is not Hankin, 1896, a phage reference? *Bacteriophage* 2011, 1, 174–178. [CrossRef] [PubMed]

6. Ackermann, H.W. On an invisible microbe antagonistic to dysentery bacilli. *C. R. Acad. Sci.* 1917, 165, 373–375.

7. Kutateladze, M.; Adamia, R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends Biotechnol.* 2010, 28, 591–595. [CrossRef] [PubMed]

8. Francino, M.P. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. *Front. Microbiol.* 2016, 6, 1543. [CrossRef] [PubMed]

9. Gindin, M.; Febvre, H.P.; Rao, S.; Wallace, T.C.; Weir, T.L. Bacteriophage for Gastrointestinal Health (PHAGE) Study: Evaluating the Safety and Tolerability of Supplemental Bacteriophage Consumption. *J. Am. Coll. Nutr.* 2018, 38, 68–75. [CrossRef]

10. Finegold, S.M.; Sutter, V.L.; Mathisen, G.E. Chapter 1—Normal Indigenous Intestinal Flora. In *Human Intestinal Microflora in Health and Disease*; Hentges, D.J., Ed.; Academic Press: Cambridge, MA, USA, 1983; pp. 3–31.

11. May, R.D.; Fung, M. Strategies targeting the IL-4/IL-13 axes in disease. *Cytokine* 2015, 75, 89–116. [CrossRef] [PubMed]

12. Gilbert, J.A.; Jansson, J.K.; Knight, R. The Earth Microbiome project: Successes and aspirations. *BMC Biol.* 2014, 12, 69. [CrossRef]

13. Callahan, B.J.; McMurdie, P.J.; Rosen, M.J.; Han, A.W.; Johnson, A.J.A.; Holmes, S.P. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* 2016, 13, 581–583. [CrossRef] [PubMed]

14. Manter, D.K.; Korsa, M.; Tebbe, C.; Delgado, J.A. myPhyloDB: A local web server for the storage and analysis of metagenomic data. *J. Biol. Database Curation* 2016. [CrossRef]

15. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet J.* 2011, 17, 10–12. [CrossRef]

16. Rognes, T.; Flouri, T.; Nichols, B.; Quince, C.; Mahé, F. VSEARCH: A versatile open source tool for metagenomics. *J. Life Environ. Sci.* 2016, 4, e2584. [CrossRef]

17. Dhariwal, A.; Chong, J.; Habib, S.; King, I.L.; Agellon, L.B.; Xia, J. MicrobiomeAnalyst: A web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. *Nucleic Acids Res.* 2017, 45, W180–W188. [CrossRef]

18. Sheflin, A.M.; Borresen, E.C.; Kirkwood, J.S.; Boot, C.M.; Whitney, A.K.; Lu, S.; Brown, R.J.; Broeckling, C.D.; Ryan, E.P.; Weir, T.L. Dietary supplementation with rice bran or navy bean alters gut bacterial metabolism in colorectal cancer survivors. *Mol. Nutr. Food Res.* 2017, 61, 1500905. [CrossRef]

19. Manning, C.D.; Schütze, H. *Foundations of Statistical Natural Language Processing*; The MIT Press: Cambridge, MA, USA, 1999.

20. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010, 26, 139–140. [CrossRef]

21. Adlerberth, I.; Wold, A.E. Establishment of the gut microbiota in Western infants. *Acta Paediatr.* 2009, 98, 229–238. [CrossRef]

22. Martinez-Guryn, K.; Hubert, N.; Frazier, K.; Urrlass, S.; Musch, M.W.; Ojeda, P.; Pierre, J.E.; Miyoshi, J.; Sontag, T.J.; Cham, C.M. Small Intestine Microbiota Regulate Host Digestive and Absorptive Adaptive Responses to Dietary Lipids. *Cell Host Microbe* 2018, 23, 458–469. [CrossRef]

23. Semova, L.; Carten, J.D.; Stombaugh, J.; Mackey, L.C.; Knight, R.; Farber, S.A.; Rawls, J.F. Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. *Cell Host Microbe* 2012, 12, 277–288. [CrossRef]

24. Brown, K.A.; Khanfer, N.; Daneman, N.; Fisman, D.N. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. *Antimicrob. Agents Chemother.* 2013, 57, 2326–2332. [CrossRef]

25. Fite, A.; Macfarlane, S.; Furr, B.; Bahrami, B.; Cummings, J.H.; Steinke, D.T.; Macfarlane, G.T. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. *J. Clin. Microbiol.* 2013, 51, 849–856. [CrossRef]
26. Kassinen, A.; Krogius-Kurikka, L.; Mäkivuokko, H.; Rinttilä, T.; Paulin, L.; Corander, J.; Malinen, E.; Apajalahti, J.; Palva, A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. *Gastroenterology* 2007, *133*, 24–33. [CrossRef]

27. Malinen, E.; Krogius-Kurikka, L.; Lyra, A.; Nikkilä, J.; Jääskeläinen, A.; Rinttilä, T.; Vilpponen-Salmela, T.; von Wright, A.J.; Palva, A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. *World J. Gastroenterol.* 2010, *16*, 4532–4540. [CrossRef]

28. Gobert, A.P.; Sagrestani, G.; Delmas, E.; Wilson, K.T.; Verriere, T.G.; Dapoigny, M.; Del’homme, C.; Bernalier-Donadille, A. The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. *Sci. Rep.* 2016, *6*, 39399. [CrossRef]

29. Matsuoka, K.; Kanai, T. The gut microbiota and inflammatory bowel disease. *Semin. Immunopathol.* 2015, *37*, 47–55. [CrossRef]

30. Scanlan, P.D.; Shanahan, F.; Marchesi, J.R. Culture-independent analysis of desulfovibrions in the human distal colon of healthy, colorectal cancer and polypectomized individuals. *FEMS Microbiol. Ecol.* 2009, *69*, 213–221. [CrossRef]

31. Muir, A.B.; Benitez, A.J.; Dods, K.; Spergel, J.M.; Fillon, S.A. Microbiome and its impact on gastrointestinal atopy. *Allergy* 2016, *71*, 1256–1263. [CrossRef]

32. Sherry, C.L.; Kim, S.S.; Dilger, R.N.; Bauer, L.L.; Moon, M.L.; Tapping, R.I.; Fahey, G.C., Jr.; Tappenden, K.A.; Freund, G.G. Sickness behavior induced by endotoxin can be mitigated by the dietary soluble fiber, pectin, through up-regulation of IL-4 and Th2 polarization. *Brain Behav. Immun.* 2010, *24*, 631–640. [CrossRef]

33. Sherer, F.; Van Simaeys, G.; Kers, J.; Yuan, Q.; Doumont, G.; Laute, M.; Peleman, C.; Egrise, D.; Lahoutte, T.; Flamand, V. Dynamic molecular imaging for hepatic function assessment in mice: Evaluation in endotoxin-induced and warm ischemia-reperfusion models of acute liver failure. *J. Liver* 2015, *4*, 1000170.

34. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.; Chabo, C. Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. *Diabetes* 2007, *56*, 1761–1772. [CrossRef]

35. Deerland Enzymes. Available online: https://www.deerlandenzymes.com/preforpro/the-science/(accessed on 18 January 2019).